LB Pharmaceuticals CFO receives 200,000-share options

The chief financial officer’s award begins vesting in 2027, with remaining options scheduled to vest monthly over three years subject to continuous service.

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller received a direct employee stock option award covering 200,000 shares of common stock on October 9, 2026. The options have an exercise price of $37.22 per share and expire October 8, 2036. Vesting is subject to Miller’s continuous service through each vesting date.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Miller Joseph M

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Emplopyee Stock Option (Right to Buy) F1	200,000	$0.00	$0.00

Holdings After Transaction: Emplopyee Stock Option (Right to Buy) — 200,000 contracts (Direct)

Footnotes (1)

1. F1. One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Shares subject to option award: 200,000 shares Exercise price: $37.22 per share Initial vesting portion: 1/4 of option-award shares +2 more

5 metrics

Shares subject to option award 200,000 shares Awarded October 9, 2026

Exercise price $37.22 per share Employee stock option

Initial vesting portion 1/4 of option-award shares Shall vest September 2, 2027

Monthly vesting begins September 30, 2027 Remaining shares vest monthly over the following three years

Option expiration October 8, 2036 Employee stock option

Key Terms

option award, vest, continuous service

3 terms

option award financial

"shares subject to the option award shall vest"

vest financial

"shall vest on September 2, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LBRX shares are covered by the CFO’s option award?

Joseph M. Miller’s option award covers options for 200,000 shares of common stock. The options have an exercise price of $37.22 per share and expire October 8, 2036.

How does Joseph Miller’s LBRX option award vest?

One-fourth of the shares subject to the option award shall vest on September 2, 2027. The remaining shares shall vest monthly over the following three years, on the last day of each month beginning September 30, 2027, subject to Miller’s continuous service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:10 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Joseph M

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Emplopyee Stock Option (Right to Buy)	$37.22	10/09/2026		A		200,000		(1)	10/08/2036	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)